Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Sep 6, 2007 9:06 AM Flag

    P2 Survival Data to be Announced..

    While the P3 data might help them target patients that will benefit most, Glufo needs to prove itself as a combo therapy to be a big winner. Sooner or later someone is going to come up with a "traditional" chemo agent that is better than Gemzar in treating pancreatic cancer - hopefully by then, Glufo will be part of the standard first-line treatment, and the new agent will be combined with Glufo. The same can be said of the other solid cancer indications - we need Glufo (or TH302) to be part of a combo therapy treatement regime!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • TH302: I'm hoping no news is good news: If time goes by without hearing that TH302 is not working in any cycle, could one assume it IS working?

      I agree with what you say re: G+G and the G, but this is really outstanding in itself that P3 was not a complete waste. I wonder how much data they can use from sub groups to reduce costs with pursuing further study.

 
THLD
4.32+0.06(+1.41%)Jul 31 4:00 PMEDT